Claims for Patent: 8,563,688

Summary for Patent: 8,563,688

Title:	Procoagulant peptides
Abstract:	A peptide or peptide derivative comprising: (i) WDLYFEIVW (SEQ ID NO: 1); or (ii) a variant amino acid sequence comprising one, two, three or four L-amino acid substitutions in WDLYFEIVW (SEQ ID NO: 1); or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. A peptide or peptide derivative comprising: (i) an amino acid sequence comprising imfwydcye; or (ii) a variant amino acid sequence comprising one, two, three, four, five or six amino acid substitutions in imfwydcye, wherein said peptide or peptide derivative has procoagulant activity.
Inventor(s):	Scheiflinger; Friedrich (Vienna, AT), Dockal; Michael (Vienna, AT)
Assignee:	Baxter International Inc. (Deerfield, IL) Baxter Healthcare SA (Glattpark (Opfikon), CH)
Application Number:	12/425,277
Patent Claims:	1. A peptide or peptide derivative comprising: (i) WDLYFEIVW (SEQ ID NO: 322); or (ii) a variant amino acid sequence comprising one, two, three or four amino acid substitutions in WDLYFEIVW (SEQ ID NO: 322), said variant amino acid sequence comprising X.sub.1X.sub.2X.sub.3YX.sub.4EX.sub.5X.sub.6X.sub.7, wherein X.sub.1 is W, L, or P; X.sub.2 is D or S, X.sub.3 is L or F, X.sub.4 is F, Phg, L, Ebw, Pff, Thi, 1Ni, Hfe, Ece or Cha, X.sub.5 is I or F, X.sub.6 is 5, V or G, and X.sub.7 is W or L (SEQ ID NO: 323) or (iii) the retro-inverso variant of the peptide or peptide derivative of either one of parts (i) and (ii), wherein said peptide or peptide derivative has procoagulant activity. 2. The peptide or peptide derivative of claim 1 wherein the variant amino acid sequence comprises an amino acid sequence comprising X.sub.1X.sub.2X.sub.3YX.sub.4EX.sub.5X.sub.6X.sub.7 wherein X.sub.1 is W or L, X.sub.2 is D or S, X.sub.3 is L or F, X.sub.4 is F, Phg or L, X.sub.5 is I or F, X.sub.6 is 5, V or G and X.sub.7 is W or L (SEQ ID NO: 324). 3. The peptide or peptide derivative of claim 1 comprising: (1) RMEFDVWDLYFEIVW (SEQ ID NO: 325); or (2) RMKFDVWDLYFEIVW (SEQ ID NO: 326); or (3) a variant amino acid sequence of RMEFDVWDLYFEIVW (SEQ ID NO: 325) or RMKFDVWDLYFEIVW (SEQ ID NO: 326), comprising between one and six amino acid substitutions of SEQ ID NO: 325 or 326, wherein, when the variant comprises one, two, three, or four amino acid substitutions in WDLYFEIVW (SEQ ID NO: 322), said variant amino acid sequence comprises X.sub.1X.sub.2X.sub.3YX.sub.4EX.sub.5X.sub.6X.sub.7, wherein said one, two, three, or four substitutions are substitutions located at X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, X.sub.6, and/or X.sub.7; wherein X.sub.1 is W, L, or P, X.sub.2 is D or S, X.sub.3 is L or F, X.sub.4 is F, Phg, L, Ebw, Pff, Thi, 1Ni, Hfe, Ece or Cha, X.sub.5 is I or F, X.sub.6 is S, V or G, and X.sub.7 is W or L. 4. The peptide or peptide derivative of claim 3 wherein the variant amino acid sequence comprises an amino acid sequence comprising X.sub.8X.sub.9X.sub.10FDVX.sub.1X.sub.2X.sub.3YX.sub.4EX.sub.5X.sub.6X.su- b.7 wherein X.sub.8 is R or P, X.sub.9 is M, Nva, Moo, N, Nle, Meo, Q, or Eag, X.sub.10 is E, K or D, X.sub.1 is W, L or P, X.sub.2 is D or S, X.sub.3 is L or F, X.sub.4 is F, Phg, L, Ebw, Pff, Thi, 1Ni, Hfe, Ece, or Cha, X.sub.5 is I or F, X.sub.6 is S, V or G and X.sub.7 is W or L (SEQ ID NO: 327). 5. The peptide or peptide derivative of claim 4 wherein the variant amino acid sequence comprises an amino acid sequence comprising X.sub.8X.sub.9X.sub.10FDVX.sub.1X.sub.2X.sub.3YX.sub.4EX.sub.5X.sub.6X.su- b.7 wherein X.sub.8 is R or P, X.sub.9 is M or Nva, X.sub.10 is E, K or D, X.sub.1 is W or L, X.sub.2 is D or S, X.sub.3 is L or F, X.sub.4 is F, Phg or L, X.sub.5 is I or F, X.sub.6 is S, V or G and X.sub.7 is W or L (SEQ ID NO: 328). 6. The peptide derivative of claim 1 which is acetylated at the N-terminus, amidated at the C-terminus and/or PEGylated at either terminus. 7. The peptide or peptide derivative of claim 1 which is cyclic. 8. The peptide or peptide derivative of claim 1 comprising or consisting of: Ac-RMKFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 329), Ac-PMKFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 330), Ac-RMDFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 331), Ac-RMEFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 332), Ac-WDLYFEIVW-NH.sub.2 (SEQ ID NO: 333), Ac-WDLYFEIVWE (SEQ ID NO: 334), Ac-WDLYFEIVW-ttds-E (SEQ ID NO: 335), ttds-RMEFDVWDLYFEIVW-ttds-NH.sub.2 (SEQ ID NO: 336), ERMEFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 337), ER(Nva)EFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 338), ttds-RMEFDVWDLY(Phg)EIVW-ttds-NH.sub.2 (SEQ ID NO: 339), Ac-WSLYFEIVWE (SEQ ID NO: 340), Ac-WDLYFEISW-ttds-E (SEQ ID NO: 341), PEG5000-RMKFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 342), PEG5000-WSLYFEIVWE (SEQ ID NO: 343), PEG5000-ERMEFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 344), Ac-VWDLYFEIVW-NH.sub.2 (SEQ ID NO: 345), Ac-FDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 346), EWDLYFEIVW-NH.sub.2 (SEQ ID NO: 347), E-ttds-WDLYFEIVW-NH.sub.2 (SEQ ID NO: 348), Ac-WDLYFEIVW-ttds-E-NH.sub.2 (SEQ ID NO: 349), Ac-RMEFDVWDLYFEIVW (SEQ ID NO: 350), RMEFDVWDLYFEIVW (SEQ ID NO: 325), Ac-K-ttds-RMEFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 351), Ac-RMEFDVWDLYFEIVWK (SEQ ID NO: 352), Ac-RMEFDVWDLYFEIVWK-NH.sub.2 (SEQ ID NO: 353), Ac-RMEFDVWDLYFEIVW-ttds-K-NH.sub.2 (SEQ ID NO: 354), Ac-WDLYFEISWE (SEQ ID NO: 355), Ac-WDLYLEIVWE (SEQ ID NO: 356), Ac-WDLYFEIVLE (SEQ ID NO: 357), WDLYFEIVW (SEQ ID NO: 322), RMEFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 358), Ac-RMEFDVWDLYFEIVW-ttds-NH.sub.2 (SEQ ID NO: 359), Ac-KRMEFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 360), K-ttds-RMEFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 361), Ac-RMEFDVWDLYFEIVW-ttds-K (SEQ ID NO: 362), Ac-LDLYFEIVW-ttds-E (SEQ ID NO: 363), Ac-WDLYFEIVL-ttds-E (SEQ ID NO: 364), ERMEFDVLDLYFEIVW-NH.sub.2 (SEQ ID NO: 365), ERMEFDVWDLYFEIVL-NH.sub.2 (SEQ ID NO: 366), Ac-WDFYFEIVWE (SEQ ID NO: 367), Ac-WDLYFEFVWE (SEQ ID NO: 368), Ac-LDLYFEIVWE (SEQ ID NO: 369), Ac-WDLYFEIGWE (SEQ ID NO: 370), Ac-WDLYLEISLE (SEQ ID NO: 371), Ac-WDLYXEIVLE (SEQ ID NO: 372), Ac-WSLYXEIVWE (SEQ ID NO: 373), Ac-LDLYFEIVLE (SEQ ID NO: 374), Ac-LDLYFEISLE (SEQ ID NO: 375), Ac-LDLYXEISWE (SEQ ID NO: 376), Ac-LSLYFEIVWE (SEQ ID NO: 377), Ac-LSLYFEIVLE (SEQ ID NO: 378), Ac-LSLYFEISLE (SEQ ID NO: 379), Ac-WDLYFEIVW-ttds-K (SEQ ID NO: 380), Ac-DVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 381), Ac-wviefyldwvdfkmr-NH.sub.2 (SEQ ID NO: 382), Ac-WDLYFEIVW (SEQ ID NO: 383), Ac-ttds-WDLYFEIVW-NH.sub.2 (SEQ ID NO: 384), ttds-WDLYFEIVW-NH.sub.2 (SEQ ID NO: 385), Ac-WDLYFEIVW-ttds-NH.sub.2 (SEQ ID NO: 386), Ac-ttds-WDLYFEIVW-ttds-NH.sub.2 (SEQ ID NO: 387), ttds-WDLYFEIVW-ttds (SEQ ID NO: 388), ttds-WDLYFEIVW-ttds-NH.sub.2 (SEQ ID NO: 389), Ac-KWDLYFEIVW-NH.sub.2 (SEQ ID NO: 390), Ac-K-ttds-WDLYFEIVW-NH.sub.2 (SEQ ID NO: 391), Ac-WDLYFEIVWK (SEQ ID NO: 392), Ac-WDLYFEIVWK-NH.sub.2 (SEQ ID NO: 393), ER(Moo)EFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 394), ERNEFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 395), ttds-RMEFDVWDLY(Ebw)EIVW-ttds-NH.sub.2 (SEQ ID NO: 396), ttds-RMEFDVWDLY(Pff)EIVW-ttds-NH.sub.2 (SEQ ID NO: 397), Ac-PDLYFEIVWE (SEQ ID NO: 398), Ac-LSLYLEIVLE (SEQ ID NO: 399), Ac-LSLYLEISLE (SEQ ID NO: 400), Ac-LSLYXEIVLE (SEQ ID NO: 401), Ac-WDLYFEIVW-ttds-K-NH.sub.2 (SEQ ID NO: 402), EPMKFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 403), ttds-RMDFDVWDLYFEIVW-ttds-NH.sub.2 (SEQ ID NO: 404), PEG5000-RMKFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 405), WDLYFEIVW-NH.sub.2 (SEQ ID NO: 406), KRMEFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 407), ttds-PMKFDVWDLYFEIVW-ttds-NH.sub.2 (SEQ ID NO: 408), ERMDFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 409), (Coh)-ttds-RMEFDVWDLYFEIVW-ttds-NH.sub.2 (SEQ ID NO: 410), Glucosyl-aminooxyacetyl-ttds-RMEFDVWDLYFEIVW-ttds-NH.sub.2 (SEQ ID NO: 411), Ac-P(Moo)KFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 412), Ac-P(Nle)KFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 413), Ac-PNKFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 414), Ac-R(Moo)DFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 415), Ac-R(Nle)DFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 416), Ac-RNDFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 417), ttds-R(Nle)EFDVWDLYFEIVW-ttds-NH.sub.2 (SEQ ID NO: 418), ttds-RNEFDVWDLYFEIVW-ttds-NH.sub.2 (SEQ ID NO: 419), ER(Nle)EFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 420), ER(Meo)EFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 421), ERQEFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 422), ER(Eag)EFDVWDLYFEIVW-NH.sub.2 (SEQ ID NO: 423), ttds-RMEFDVWDLY(Thi)EIVW-ttds-NH.sub.2 (SEQ ID NO: 424), ttds-RMEFDVWDLY(1Ni)EIVW-ttds-NH.sub.2 (SEQ ID NO: 425), ttds-RMEFDVWDLY(Hfe)EIVW-ttds-NH.sub.2 (SEQ ID NO: 426), ttds-RMEFDVWDLY(Ece)EIVW-ttds-NH.sub.2 (SEQ ID NO: 427), ttds-RMEFDVWDLY(Cha)EIVW-ttds-NH.sub.2 (SEQ ID NO: 428), KWDLYFEIVW-NH.sub.2 (SEQ ID NO: 429), or K-ttds-WDLYFEIVW-NH.sub.2 (SEQ ID NO: 430), wherein -ttds- is 4,7,10-trioxa-1,13-tridecanediamine, (Nva) is norvaline, (Phg) is phenylglycine, (Coh) is cysteic acid, (Moo) is methioninesulfone, (Ebw) is 3,3-diphenylalanine, (Pff) is 4'-fluorophenyl-alanine, (Nle) is norleucine, (Meo) is methioninesulfoxide, (Eag) is propargylglycine, (Thi) is 2-thienylalanine, (1Ni) is 1-naphthyl-alanine, (Hfe) is homophenylalanine, (Ece) is s-benzyl-L-cysteine, (Cha) is cyclohexylalanine. 9. The peptide or peptide derivative as defined in claim 1 conjugated to a further peptide or peptide derivative as defined in any of claims 1 to 8, wherein the peptide or peptide derivative is the same as or different from the further peptide or peptide derivative, and wherein the peptide or peptide derivative conjugated to the further peptide or peptide derivative has procoagulant activity. 10. The peptide or peptide derivative of claim 1 which has a molecular weight of between 0.5 and 3.5 kD. 11. The peptide or peptide derivative of claim 1, wherein the procoagulant activity is a thrombin generation time of 25, 50 or 100 .mu.M of peptide or peptide derivative equivalent to that of at least 100 mU/mL Factor Eight Inhibitor Bypassing Activity (FEIBA), at least 300 mU/mL FEIBA, at least 900 mU/mL FEIBA, or at least 1200 mU/mL FEIBA in the Defined Intrinsic Thrombin Generation Assay. 12. The peptide or peptide derivative of claim 1, wherein the procoagulant activity is a thrombin generation time of 25, 50 or 100 .mu.M of peptide or peptide derivative in a Defined Intrinsic Thrombin Generation Assay peaking within 30 minutes, within 15 minutes or within 10 minutes. 13. The peptide or peptide derivative of claim 1 which can at least partially compensate for the absence of biologically active FVIII when administered in an animal model of severe human hemophilia A. 14. The peptide or peptide derivative of claim 1 which has a stability in human plasma at 30 minutes of at least 50%, at least 70%, at least 80% or at least 90%. 15. The peptide or peptide derivative of claim 1 which has an aqueous solubility in phosphate buffered saline pH 7.4 of at least 25 .mu.M, at least 60 .mu.M or at least 100 .mu.M. 16. A pharmaceutical composition comprising the peptide or peptide derivative of claim 1 and one or more pharmaceutically acceptable excipients, carriers and/or diluents. 17. The pharmaceutical composition of claim 16 suitable for subcutaneous, nasal, buccal, oral or pulmonary administration. 18. The pharmaceutical composition of claim 17 suitable for intravenous administration. 19. A method of treating a patient having a deficiency in FV, FVII, FVIII, FX and/or FXI comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 16. 20. A method of treating a patient having a deficiency in FV, FVII, FVIII, FX and/or FXI comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 17. 21. A method of treating a patient having a deficiency in FV, FVII, FVIII, FX and/or FXI comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 18. 22. The method of claim 19, wherein the patient has inhibitor antibodies against FV, FVII, FVIII, FX and/or FXI. 23. The peptide or peptide derivative of claim 1, wherein the peptide or peptide derivative is not FVIII or a fragment thereof and, wherein the procoagulant activity is a thrombin generation time of 25, 50 or 100 .mu.M of peptide, peptide derivative or dual peptide equivalent to that of at least 100 mU/mL Factor Eight Inhibitor Bypassing Activity (FEIBA), preferably at least 300 mU/mL FEIBA, more preferably at least 900 mU/mL FEIBA, most preferably at least 1200 mU/mL FEIBA in the Defined Intrinsic Thrombin Generation Assay. 24. The peptide or peptide derivative of claim 1, wherein the peptide or peptide derivative is not FVIII or a fragment thereof and, wherein the procoagulant activity is a thrombin generation time of 25, 50 or 100 .mu.M of peptide, peptide derivative or dual peptide in a Defined Intrinsic Thrombin Generation Assay peaking within 30 minutes, preferably within 15 minutes and most preferably within 10 minutes. 25. The peptide or peptide derivative of claim 1, wherein the peptide or peptide derivative is not FVIII or a fragment thereof and, wherein the peptide or peptide derivative can at least partially compensate for the absence of biologically active FVIII when administered in an animal model of severe human hemophilia A.

Details for Patent 8,563,688

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Baxalta Us Inc.	AUTOPLEX, FEIBA NF, FEIBA VH	anti-inhibitor coagulant complex	For Injection	101447	12/21/1979		2028-04-17
Baxalta Us Inc.	AUTOPLEX, FEIBA NF, FEIBA VH	anti-inhibitor coagulant complex	For Injection	101447	07/31/2000		2028-04-17
Baxalta Us Inc.	AUTOPLEX, FEIBA NF, FEIBA VH	anti-inhibitor coagulant complex	For Injection	101447	08/11/2005		2028-04-17